Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Other, Topics Aug 15 | 2025Lilly Addresses Global Drug Cost Changes; BioAge Ph1 NLRP3i Trial UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 14 | 2025Zealand Q2 ‘25 Earnings; Lilly Raises Mounjaro Prices in UK; Lilly Partners with Superluminal for Obesity Drug Discovery Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Aug 13 | 2025Ascletis Preclinical Obesity Data; Sagimet Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Autologous, Dual/triple agonist, Other, Topics Aug 12 | 2025UK Partners with Lilly for Obesity Program; Altimmune and Veru Q2 ‘25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Aug 11 | 2025Medtronic Discloses its Abbott-Partnered CGM; Viking Registers Ph3 VK2735 Program; Roche Initiates H2H CT-996 vs Rybelsus in T2DM; Veru Shares New Formulation for EnobosarmPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 08 | 2025Tandem, Skye, Arrowhead, Gilead, Xeris, Viatris, Biocon, and 89bio Q2 ‘25 Earnings; Novo’s US Marketing Head Steps Down Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Aug 07 | 2025Novo London, Insulet, Senseonics, and MetaVia Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Aug 07 | 2025Lilly Leaves Door Open for Novo; Lilly Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 07 | 2025Amgen and MannKind Q2 ’25 Earnings; Sava Raises $19M for Biosensor Development; MetaVia Extends Ph1 Obesity Study Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Aug 07 | 2025Novo Cleans Out Pipeline; Q2 ‘25 Earnings Update Purchase Blast
$599
Posted in: Autologous, Dual/triple agonist, GLP-1RA, Other, Topics Aug 06 | 2025Novo Sues Compounders…Again; Pfizer, Madrigal, Vertex, Corbus, and Esperion Q2 ‘25 Earnings; Innovent Receives IND clearance for Oral GLP-1RA; Vivani Data for Semaglutide Implant Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 04 | 2025Noom to Sell “Microdoses” of Wegovy; Sanofi Initiates Ph3 Tzield Study; MetaVia Partners for TA Discovery; Ypsomed Completes Sale of Diabetes Care Business Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Aug 04 | 2025Regeneron Q2 ‘25 Earnings; Medicare + Medicaid Potentially to Cover AOMs; Leqvio Label Expansion as MonotherapyPurchase Blast
$599
Posted in: Autologous, Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 01 | 2025Mounjaro SURPASS-CVOT Results; Dexcom, Sanofi, AbbVie, and Alnylam Q2 ‘25 Earnings; Novo Initiates Ph1 T1DM FGF21 Study Purchase Blast
$599
Posted in: Basal Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jul 31 | 2025Madrigal Acquires Oral GLP-1RA; Beta Bionics, Ionis, and Teva Q2 ‘25 Earnings; Tidepool/Abbott Integration Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 30 | 2025AstraZeneca, Merck, and Metsera Q2 ‘25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 30 | 2025Novo Appoints Mike Doustdar as CEO; Lowers FY ’25 GuidancePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jul 29 | 2025Lilly Initiates Ph2 Naperiglipron Trial; Dexcom Launches AI Meal-Tracking Feature; Trinity Announces New CGM+; Ascletis Ph2 Obesity Trial UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Insulin Delivery, Other, Topics Jul 28 | 2025Sciwind GLP-1RA Licensing Rumors; Lilly Completes Verve Acquisition; Adocia Ph3 Insulin Lispro Data Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jul 24 | 2025Roche, Viking, and BI Q2 ‘25 Earnings; Novo Discontinues Insulin Purchase Blast